Literature DB >> 8161668

Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy.

S Gore1, C J Healey, R Sutton, I A Eyre-Brook, M W Gear, N A Shepherd, S P Wilkinson.   

Abstract

Twenty-three adult patients with a columnar lined (Barrett's) oesophagus are being treated with long-term omeprazole, 40 mg daily. Twelve had never undergone anti-reflux surgery (Group 1), the other eleven having previously had insertion of an Angelchik anti-reflux prosthesis (Group 2). Endoscopy was carried out six months before, immediately before and six months, one year and two years into treatment. Multiple and standardized biopsies were taken at each endoscopy. Results from the two groups were similar. During the 6-month run-in period there was a statistically non-significant increase in the linear extent of the columnar mucosa, but this showed a progressive, statistically significant decrease during the two years of treatment. Other evidence for regression of the Barrett's mucosa includes the emergence of large numbers of macroscopic squamous islands within the abnormal mucosa, an increase in the number of microscopic squamous islands, and microscopic squamous encroachment of the abnormal mucosa at the squamo-columnar junction. Histological assessment showed a reduction in the proportion of sulphomucin-rich intestinal metaplasia, but this only achieved statistical significance in Group 1. The results substantiate the importance of acid in the pathogenesis of Barrett's oesophagus. Omeprazole may have a therapeutic role in bringing about regression of the metaplastic epithelium.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8161668     DOI: 10.1111/j.1365-2036.1993.tb00143.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  29 in total

1.  Barrett's oesophagus and proton pump inhibitors: a pathological perspective.

Authors:  N A Shepherd
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

2.  Proton pump inhibitors for Barrett's oesophagus.

Authors:  G Triadafilopoulos
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

Review 3.  Digestive system disorders: gastroesophageal reflux disease.

Authors:  D A Katzka
Journal:  West J Med       Date:  2000-07

4.  Combination of endoscopic argon plasma coagulation and antireflux surgery for treatment of Barrett's esophagus.

Authors:  H Tigges; K H Fuchs; J Maroske; M Fein; S M Freys; J Müller; A Thiede
Journal:  J Gastrointest Surg       Date:  2001 May-Jun       Impact factor: 3.452

Review 5.  Barrett's esophagus: environmental influences in the progression of dysplasia.

Authors:  Ralph A Boulton; Bernhard Usselmann; Imtiyaz Mohammed; Janusz Jankowski
Journal:  World J Surg       Date:  2003-07-28       Impact factor: 3.352

Review 6.  Barrett's oesophagus: the new endoscopic modalities have a future.

Authors:  J Deviere
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

7.  Epithelial cell proliferative activity of Barrett's esophagus: methodology and correlation with traditional cancer risk markers.

Authors:  F T Peters; S Ganesh; E J Kuipers; A de Jager-Krikken; A Karrenbeld; G Harms; W J Sluiter; J Koudstaal; E C Klinkenberg-Knol; C B Lamers; J H Kleibeuker
Journal:  Dig Dis Sci       Date:  1998-07       Impact factor: 3.199

8.  Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers.

Authors:  G Morgan
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

9.  Long-term follow-up after complete ablation of Barrett's esophagus with argon plasma coagulation.

Authors:  Ahmed Madisch; Stephan Miehlke; Ekkehard Bayerdorffer; Birgit Wiedemann; David Antos; Anke Sievert; Michael Vieth; Manfred Stolte; Heinrich Schulz
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

10.  Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results.

Authors:  J L Van Laethem; M Cremer; M O Peny; M Delhaye; J Devière
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.